Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 18, 2022 - Issue 3: The JAKi in inflammatory disorders & arthritis: lights and shadows
Submit an article Journal homepage
4,304
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Do JAK inhibitors have a realistic future in treating Crohn’s disease?

Tommaso Lorenzo Parigia Department of Biomedical Sciences, Humanitas University, Milan, Italy;b Institute of Immunology and Immunotherapy and NIHR Wellcome Trust Clinical Research Facility, University of Birmingham, Birmingham, UKORCID Iconhttps://orcid.org/0000-0002-3398-0231View further author information
ORCID Icon,
Virginia Solitanoa Department of Biomedical Sciences, Humanitas University, Milan, ItalyView further author information
,
Laurent Peyrin-Birouletc Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, FranceView further author information
&
Silvio Danesed Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7341-1351View further author information
ORCID Icon
Pages 181-183 | Received 10 Sep 2021, Accepted 15 Dec 2021, Published online: 31 Dec 2021

References

  • Rogler G. Efficacy of JAK inhibitors in Crohn’s disease. J Crohns Colitis. 2020;14(Supplement_2):S746–54.
  • Günther C, Ruder B, Stolzer I, et al. Interferon lambda promotes Paneth cell death via STAT1 signaling in mice and is increased in inflamed ileal tissues of patients with Crohn’s disease. Gastroenterology. 2019;157(5):1310–1322.e13.
  • Wang L, Hu Y, Song B, et al. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease. Inflamm Res. 2021;70(7):753–764.
  • Salas A, Hernandez-Rocha C, Duijvestein M, et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(6):323–337.
  • Danese S, Argollo M, Le Berre C, et al. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut. 2019;68(10):1893–1899.
  • D’Amico F, Parigi TL, Fiorino G, et al. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol. 2019;12:1756284819848631.
  • Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(9):1485–1493.e2.
  • Panés J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66(6):1049–1059.
  • Feagan BG, Danese S, Loftus EV, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397(10292):2372–2384.
  • Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266–275.
  • Gilead sciences combined phase 3, double-blind, randomized, placebo-controlled studies evaluating the efficacy and safety of filgotinib in the induction and maintenance of remission in subjects with moderately to severely active Crohn’s disease. clinicaltrials.gov; 2021.
  • Sandborn WJ, Feagan BG, Loftus EV, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology. 2020;158(8):2123–2138.e8.
  • Parigi TL, D’Amico F, Danese S. Upadacitinib for Crohn’s disease and ulcerative colitis treatment: hitting the selective JAKpot. Gastroenterology. 2021;160(5):1472–1474.
  • Solitano V, Fiorino G, D’Amico F, et al. Thrombosis in IBD in the Era of JAK Inhibition. Curr Drug Targets. 2021;22(1):126–136.
  • Research C for DE and. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. FDA; 2021.
  • Danese S, Peyrin-Biroulet L. Selective tyrosine kinase 2 inhibition for treatment of inflammatory bowel disease: new hope on the Rise. Inflamm Bowel Dis. 2021;27(izab135):2023–2030.
  • Lee SD, Singla A, Harper J, et al. Safety and efficacy of tofacitinib in combination with biologic therapy for refractory Crohn’s disease. Inflamm Bowel Dis. 2021;(izab176). DOI:https://doi.org/10.1093/ibd/izab176
  • Alayo QA, Khatiwada A, Patel A, et al. Effectiveness and safety of combining tofacitinib with a biologic in patients with refractory inflammatory bowel diseases. Inflamm Bowel Dis. 2021;27(10):1698–1702.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.